Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in HIV/AIDS Patients: A Randomized Controlled Trial

(2012) Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in HIV/AIDS Patients: A Randomized Controlled Trial. Hepatitis Monthly. p. 6. ISSN 1735-143X

[img] Text
Effects of oral levamisole as an adjuvant to hepatitis B Vaccine in HIVAIDS Patients A randomized controlled trial.pdf

Download (912kB)

Official URL:


Background: Human immunodeficiency virus (HIV) infected patients are also frequently exposed to the hepatitis B virus (HBV), due to the common routes of transmission, therefore, prevention of hepatitis B results in decreased complications of the disease. Objectives: Since the immune response of HIV patients to hepatitis B vaccination is less robust than that found in healthy individuals, this study aimed to evaluate the effect of a levamisole adjuvant on increasing the immune response. Patients and Methods: In this study, 89 HIV infected patients, without a history of HBV infection or vaccination, were randomly allocated into experimental (44 patients) and control (45 patients) groups. HBV vaccination was performed using the Hepavax-Gene TF vaccine, 40 mu g three times at intervals of; zero, one, and three months. Levamisole 50 mg twice a day or a placebo, was administered to the experimental and control groups, respectively, for a period of six days before to six days after the vaccination. Immune response was evaluated by measuring hepatitis B surface antibodies (HBsAb) concurrently with the second and third vaccine administration, and at one and three months at the conclusion of the vaccination program. Results: The immune response following the threevaccinations was higher in those who were receiving levamisole compared with the controls (90 vs. 65.38) (P = 0.05). Furthermore, the immune response and the mean antibody titer following the repeated vaccination in the experimental group showed a higher increase than in the control group. The immune response and the mean titer of antibody were not associated with; age, sex, body mass index, history of smoking and/or intravenous drug use in either of the groups. However, regarding CD4+ cells more than 200 cell/mm3, mean antibody production significantly increased in both groups. Conclusions: Using levamisole with the hepatitis B vaccination can increase the immune response and antibody titer mean in HIV infected patients. Since these patients have a more complete response with CD4+ cells more than 200 cell/mm3, vaccination and effective adjuvants seem to be most beneficial when CD4+ cells are greater than 200 cell/mm3, in HIV infected patients. Published by Kowsar Corp, 2012. cc 3.0.

Item Type: Article
Keywords: HIV Hepatitis B Virus Vaccination Levamisole infected adult patients hemodialysis-patients immune-response antibody Gastroenterology & Hepatology
Page Range: p. 6
Journal or Publication Title: Hepatitis Monthly
Journal Index: ISI
Volume: 12
Number: 9
Identification Number:
ISSN: 1735-143X
Depositing User: مهندس مهدی شریفی

Actions (login required)

View Item View Item